Previous Financial Rounds
INVITATION TO SUBSCRIBE FOR SHARES IN S2MEDICAL AB (PUBL)
Rights Issue
S2Medical AB (publ) carries out a rights issue of SEK 21.2 million.
S2Medical aims to change the wound care industry by replacing today's wound care treatments with a holistic concept for wound healing. In order to finance the continued development and be able to lead the wound care industry toward wound healing, S2Medical has decided to finance the expansion through an Issue of new shares.
The rights issue is guaranteed to 85 percent of subscription commitments and guarantee commitments.
To cover a possible over-allotment in connection with the rights issue, the Company's Board of Directors, with the support of authorization from the Annual General Meeting, has undertaken to issue a maximum of 666,667 new Class B shares corresponding to SEK 5.0 million through a directed new share issue.
The price for shares in the over-allotment issue will be the same as the price in the rights issue, ie SEK 7.50 / share.
Issue terms in summary
Issue volume: SEK 21.2 million
Over-allotment option: SEK 5.0 million
Subscription price: SEK 7.50 per share.
Subscription period: 20 Nov - 4 Dec 2020
An innovative company with the goal of revolutionizing wound healing
S2Medical has developed innovative medical technology products throughout the wound healing process, from debridement and granulation to re-epithelialization. That is, products for the initial phase of a wound healing process to the end when the wound is completely healed. The company's main products are dressings from S2Medical's EPIPROTECT® series, which are based on the innovative eiratex® technology and are intended for the treatment of burns and chronic wounds.
S2Medical's production facility in Linköping has a production capacity of up to 30,000 units per month. The company's precise and controlled production gives the material unique properties in the form of very high formability, transparency, strength, and breathability. The eiratex® material shares the nanostructure of human skin, giving the product a very high biocompatibility and full functionality as a cell-free biosynthetic membrane. The membrane is gas permeable at the same time as it buffers moisture, which enables a perfect environment and the right conditions for the wound during the entire healing process.
The company has been a reseller of the antimicrobial product Silverlon since 2019. In other respects, the company lacked its own antimicrobial product line, which led to an agreement to acquire the company Curenc AB, in October 2020, in order to utilize this company's patented technology for antimicrobial peptides. Curenc AB has not yet been taken over by S2Medical AB as of the date of the memorandum. Access is expected to take place in December 2020. This technology is intended to be commercialized in several different stages where the product that is expected to be the first on the market is a skin cream that can counteract the spread of bacteria from the skin to a nearby wound. S2Medical also plans to manufacture an antibacterial version of EPIPROTECT® based on this technology.
More about S2Medical AB (publ)
S2Medical is an innovative medical technology company founded in 2013 with headquarters in Linköping. S2Medical develops and sells wound healing products with a focus on burns and chronic wounds. The company has developed eiratex®, a new cellulose-based material for healing both burns and chronic wounds. eiratex® is produced in its own production facility in Linköping and heals wounds efficiently, often completely without the need for a dressing change. As the need for dressing changes is virtually eliminated, the dressing both means an increased quality of life for the patient and can lead to large cost savings for healthcare. With the help of the material eiratex®, obstacles to the establishment in the form of ethical and religious contradictions that exist in relation to current methods of using animal and human skin are also avoided.
Since 2013, the company has built strong relationships and a well-established network of distributors who, in combination with their own marketing and sales units, form the platform for delivering innovative medical technology products for wound healing.
S2Medical's products based on eiratex® technology are CE marked and may be marketed within the EU region and in several countries in the Middle East. The company has received regulatory approvals for seven markets outside Europe. As of September 30, 2020, the Company had agreed to distributors in the United Kingdom, Italy, France, and Germany in Europe in addition to direct sales in the Nordic region. As of September 30, 2020, the company also had agreements with seven established distributors outside Europe, which together cover approximately 10 markets in the Middle East, Asia, and Africa.
On October 15, 2018, the Company opened S2Clinic, a wound healing clinic completely focused on healing wounds with the help of S2Medical's holistic concept of wound healing. Through the establishment of S2Clinic, S2Medical intends to generate revenue through the treatment of chronic wounds, consultations, and clinical studies, while S2Medical gets close contact with end customers, the opportunity to demonstrate the in-house developed products and demonstrate all the benefits of S2Medical's products and wound healing strategy. The long-term goal of S2Clinic is to, in parallel with the sale of the products, establish a network of franchise clinics where S2Medical's unique working methods are combined with its own product portfolio. For more information about S2Clinic.
Since the stock exchange listing in November 2018, S2Medical has intensified market processing in Europe and the Middle East. The expansion has taken place by expanding resources in personnel, marketing, and sales. Great focus has been placed on preparing the Company and its products for participation in procurements, which is a prerequisite for a larger market establishment. The company has also invested in the production of the EPIPROTECT® series to be able to produce several units per day.
Watch investor presentation from the share 23 Oct 2018 in Stockholm.
In connection with the share day in Stockholm, the company's CEO, Petter Sivlér and COO, Mårten Skog presented S2Medical AB (publ) and its operations.
Watch when Petter Sivlér, CEO of S2Medical AB (publ) presents the business ahead of the 2018 stock exchange listing.
